Standout Papers

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 i... 2014 2026 2018 2022 343
  1. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study (2014)
    Bonaventura Clotet, Judith Feinberg et al. The Lancet

Immediate Impact

1 from Science/Nature 61 standout
Sub-graph 1 of 20

Citing Papers

Mechanisms of long COVID and the path toward therapeutics
2024 Standout
Platinum Nanoparticles Regulated V2C MXene Nanoplatforms with NIR‐II Enhanced Nanozyme Effect for Photothermal and Chemodynamic Anti‐Infective Therapy
2024 Standout
4 intermediate papers

Works of Roberto Ortiz being referenced

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
2014 Standout
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
2008
and 1 more

Author Peers

Author Last Decade Papers Cites
Roberto Ortiz 952 270 241 619 16 1.0k
Joseph G. Jemsek 929 428 242 632 18 1.3k
Winkler G. Weinberg 967 572 146 407 21 1.3k
Scott Brun 1168 123 337 919 17 1.3k
Jonathan Ainsworth 780 481 235 510 43 1.1k
Asda Vibhagool 854 447 195 470 36 1.2k
J. P. Chave 703 428 166 308 19 922
Ruth Goodall 584 238 116 368 46 873
Michelle Jones 643 415 84 513 23 1.3k
Jean‐Philippe Chave 848 488 467 488 21 1.3k
Roel A. Coutinho 622 533 82 611 27 1.1k

All Works

Loading papers...

Rankless by CCL
2026